OTT-CSIC: TECHNOLOGY TRANSFER OFFICE
  SPANISH COUNCIL FOR SCIENTIFIC RESEARCH   SPANISH COUNCIL FOR SCIENTIFIC RESEARCH
      TECHNOLOGY TRANSFER OFFICE
Start | TECHNOLOGY OFFER | NEWS | CONTACT | ESPAÑOL |Go Back
 
 
OTT-CSIC-> Catalogue -> Technologies by Areas -> Biology / Biomedicine ->
CSIC BIO056- New inducer for the regulation of gene expresion.
Institute of Microbial Biochemistry of CSIC has obtained a tiopeptidic compound, which induces the tipA promoter, which can be used in different expression vectors for Streptomyces, to obtain a regulated expression of genes of interest. The research group is looking for a biotechnology company that is interested in financing and license agreements.
Specification sheet:
DESCRIPTION

Radamicina is a tiopeptidic molecule produced by a new strain of Streptomyces isolated in Salamanca, Spain ( Streptomyces sp RSP9). This compound can be found in the supernatant of these bacterial cultures and inside the cells or bound to them. The purified radamicine does not present an antibiotic activity against Gram positive bacteria unlike other tiopeptide molecules. However, it presents a high induction activity of the tipA promoter.

Its major advantage is being a powerful inducer of the tipA promoter, but without showing an antibiotic activity. The tipA promoter, that presents a potent and inducible activity, can be used in different expression vectors of Streptomyces, to obtain a regulated expression of genes of interest. Radamycin is the first inductor of this promoter which does not present antibiotic activity, and this is its major advantage. It is also important to remark the fact that the use of radamicine can reduce the use of tiopeptide antibiotics as it doesn`t present any antibiotic activity. This fact avoids the addition of antibiotics to the culture medium and the presence of antibiotic resistance genes in the host strain, which induces undesirable physiological modifications. Another unwanted side effect could be the uncontrolled distribution of resistance genes to tiopeptide compounds with antibiotic activity.

INNOVATIVE ASPECTS

Different tiopeptidic antibiotics induce the tipA promoter. However, the compound described in this technology offer presents the advantage of inducing the tipA promoter without having an antibiotic activity.

Since radamycin does not have antibiotic activity but is structurally very similar to other biologically active compounds it could be used to study the mechanism of acction of these type of molecules.

COMPETITIVE ADVANTAGES

Radamycin induces the tipA promoter without having an antibiotic activity so it can be used with vectors lacking tiopeptide antibiotic resistance marker.

KEYWORDS

006001015 Virus, Virology / Antibiotics / Bacteriology

006002004 Microbiology

006003001 Biochemistry / Biophysics

PATENT

ES 200102609, applied for at 2002-01-11

CONTACT

Javier Etxabe
email: j.etxabe@orgc.csic.es
phone: +34 91 585 53 75

FOR MORE CSIC TECHNOLOGY OFFERS CLICK HERE

If you wish more information about the product/service, please fill-out the next form.

Tell a friend

 
 
Serrano, 113. 28006-Madrid (Spain). TEL: +34 91 585 53 01, FAX: +34 91 585 52 87, mail: ott@csic.es
CSIC.2005. It is allowed to use the text and information contained in these pages. Nevertheless, it is required previous permission of OTT-CSIC for their distribution or publication in any support accessible to third parties..